Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab

Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab

<b>Background/Objectives</b>: The aim of our study was to investigate B cell and T cell responses in people with multiple sclerosis (PwMS) treated with ocrelizumab, a humanized anti-CD20 antibody, who were vaccinated with second and/or booster doses of various vaccine brands against COVI...

Full description

Saved in:
Bibliographic Details
Main Authors: Jelena Drulovic, Olivera Tamas, Neda Nikolovski, Nikola Momcilovic, Vanja Radisic, Marko Andabaka, Bojan Jevtic, Goran Stegnjaic, Milica Lazarevic, Nikola Veselinovic, Maja Budimkic, Sarlota Mesaros, Djordje Miljkovic, Tatjana Pekmezovic
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Vaccines
Subjects:
multiple sclerosis
ocrelizumab
COVID-19
vaccine response
seroconversion
Online Access:https://www.mdpi.com/2076-393X/13/5/488
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items